GOTHENBURG, SE / ACCESSWIRE / May 28, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 28, 2024 - IRLAB Therapeutics…
KITCHENER, ON / ACCESSWIRE / May 27, 2024 / Cloud DX (TSXV:CDX)(OTCQB:CDXFF), will post its Q1-2024 financial results after market…
STOCKHOLM, SWEDEN / ACCESSWIRE / May 27, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) PMD Device Solutions AB (publ) cancels the…
Detroit, Michigan--(Newsfile Corp. - May 27, 2024) - James Anderson and Life Beyond Barriers, LLC (together, the "Investor") filed an…
Mississauga, Ontario--(Newsfile Corp. - May 27, 2024) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), an emerging player in…
Toronto, Ontario--(Newsfile Corp. - May 27, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light…
GOTHENBURG, SE / ACCESSWIRE / May 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 27, 2024 - IRLAB Therapeutics…
72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;Rapid and sustained improvements in hematuria over 36…
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine)…
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label…